BCL2, BCL2 apoptosis regulator, 596

N. diseases: 1456; N. variants: 27
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. 31320555 2020
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clinical trials, and they were further discovered to have synergistic interactions. 30594434 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE Translocation t(11;14) has emerged as the first predictive marker in MM, indicating susceptibility to BCL2 inhibition. 31818702 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE Ex vivo pharmacodynamic analyses demonstrated that the combination of JQ1 and ricolinostat led to significantly lower MM cell proliferation and increased apoptosis and diminished expression of c-MYC and BCL-2. 31015208 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE Exosome-transmitted LINC00461 promotes multiple myeloma cell proliferation and suppresses apoptosis by modulating microRNA/BCL-2 expression. 30409700 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE Taken together, miR‑497 suppressed MM cell proliferation and promoted apoptosis by directly targeting Bcl‑2 and altering the expression of downstream apoptosis‑related proteins. 30535471 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE Co-culture experiments resulted in MDSC-induced AMPK phosphorylation in MM cells, which was associated with an increase in the anti-apoptotic factors MCL-1 and BCL-2, and the autophagy-marker LC3II. 30419344 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE Moreover, miR-324-5p potentiated the anti-MM efficacy of bortezomib through regulating the activities of multidrug-resistance proteins and the expression of Bcl-2 family genes. 28905994 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE Venetoclax, an oral BH3 mimetic inhibiting BCL2, showed single agent activity in MM with t(11;14), and is being studied in combination with bortezomib/dexamethasone. 29257139 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE ABT-199 is a specific Bcl-2 inhibitor in clinical trials for MM; however, its activity as a single agent was limited to myeloma patients with the t(11;14) translocation who acquire resistance due to co-expression of Mcl-1 and Bcl-xL. 29761903 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE This review addresses the role and regulation of pro-survival BCL-2 family proteins during healthy PC differentiation and in MM, as well as their potential as therapeutic targets. 30524962 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE Approximately, 20% of myeloma patients will exhibit <i>t</i> (11;14) associated with high BCL-2 expression making venetoclax an attractive therapeutic option. 30428277 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE In myeloma, in vitro sensitivity to venetoclax is mainly observed in plasma cells harboring the t(11;14) translocation, a molecular subgroup associated with high Bcl-2 and low Mcl-1/Bcl-XL expression. 30076373 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE BCL-2 mRNA was significantly higher in the bone marrow mononuclear cells from MM patients. 30170425 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE The transcription of several gene products was found to be either commonly overexpressed (i.e., RKIP, Bcl-2, and DR5) or underexpressed (i.e., Bcl-6 and TNFR2) in both pre-MM and MM. 28476134 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE MM.1R and MM.1S cell lines were treated with 15d-PGJ<sub>2</sub> at 1-10μM and evaluated with regard to proliferation, mRNA expression of PRDX1, PRDX4, GRP78, GRP94, CHOP, BCL-2 and BAX. 28506771 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE Venetoclax is a selective, orally bioavailable BCL-2 inhibitor that induces cell death in multiple myeloma (MM) cells, particularly in those harboring t(11;14), which express high levels of BCL-2 relative to BCL-X<sub>L</sub> and MCL-1. 29018077 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE The antiapoptotic proteins BCL-2 and myeloid cell leukemia sequence 1 (MCL-1) promote multiple myeloma (MM) cell survival. 28847998 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE ASA may potentiate the antimyeloma activity of BTZ against myeloma cells via suppression of AKT phosphorylation, survivin and Bcl-2, indicating the potential of ASA+BTZ in treating MM, particularly for cases of BTZ-refractory/relapsed MM. 28356941 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE We used the Bcl-2/Bcl-x<sub>L</sub> inhibitor ABT-737 to study the factors regulating whether myeloma is Mcl-1 dependent, and thus resistant to ABT-737-induced apoptosis, or Bcl-2/Bcl-x<sub>L</sub> codependent, and thus sensitive to ABT-737. 28151428 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE Multiple myeloma xenograft models that coexpressed BCL-XL or MCL-1 with BCL-2 were also resistant to venetoclax. 26939706 2016
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. 27465916 2016
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE Ritonavir and metformin effectively suppressed AKT and mTORC1 phosphorylation and prosurvival BCL-2 family member MCL-1 expression in multiple myeloma cell lines in vitro and in vivo. 25542900 2015
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 AlteredExpression disease BEFREE High BCL2 levels have been detected in most human lymphoid malignancies, not limited to follicular lymphoma (where the role of BCL2 overexpression is driven by the t[14;18] translocation) but also B-cell chronic lymphocytic leukemia (CLL) and multiple myeloma. 24095849 2014
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma
0.400 Biomarker disease BEFREE Myeloid cell leukemia-1 (Mcl-1, HGNC: 6943), a pro-survival member of the Bcl-2 family, plays a crucial role in Multiple Myeloma (MM) pathogenesis and drug resistance, thus representing a promising therapeutic target in MM. 24120758 2014